U.S. Markets close in 2 hrs 11 mins

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.100-0.050 (-2.326%)
As of 1:44PM EDT. Market open.
People also watch
Full screen
Previous Close2.150
Bid2.100 x 200
Ask2.120 x 500
Day's Range2.010 - 2.200
52 Week Range0.780 - 5.590
Avg. Volume2,752,282
Market Cap32.72M
PE Ratio (TTM)-1.23
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
    Capital Cube28 days ago

    Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis Æterna Zentaris, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Æterna Zentaris, Inc. – Spectrum Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., Bristol-Myers Squibb Company, Sanofi Sponsored ADR, Novartis AG Sponsored ADR, Halozyme Therapeutics, Inc. and Theratechnologies Inc. (SPPI-US, KERX-US, ... Read more (Read more...)

  • Associated Presslast month

    Aeterna Zentaris reports 2Q loss

    The Montreal-based company said it had a loss of 18 cents per share. Losses, adjusted for non-recurring gains, were 46 cents per share. The drug developer posted revenue of $243,000 in the period. In the ...

  • SmarterAnalyst2 months ago

    AEterna Zentaris Inc. (USA) (AEZS) CEO’s Departure Raises Questions

    AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are tumbling nearly 7% in Monday's trading session, following the news that CEO David Dodd is stepping down and will be succeed by Michael Ward. Most recently, Ward served as Chief Compliance & Legal Officer and Corporate Secretary for Sagent Pharmaceuticals and led its sale to Nichi-Iko Pharmaceutical for $736 million. If David Dodd turned around AEZS, why is he out?